Skip to main content

Table 1 Patient background characteristics

From: Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

Background characteristicsMeanMedian
Age59.261.0
Disease duration (months)80.236.0
Number of swollen joints8.27.0
Number of tender joints9.48.0
DAS28ESR5.75.7
DAS28CRP5.04.9
ESR (mm/h)51.447.5
CRP (mg/dL)2.61.2
RF (IU/mL)164.964.4
MMP-3 (ng/mL)272.5152.0
Dose of MTX (mg/week)9.710.0
Dose of GC (mg/day in prednisolone equivalent)1.30.0
Failure in csDMARDs2.02.0
 FrequencyPercent
GenderFemale130781.0
Male30719.0
Entry phaseI1157.1
II44227.4
III105665.5
BiologicsIFX64339.8
ETA37223.1
ADA40425.0
GLM251.6
CZP17010.5
Use of corticosteroid44627.6
Use of MTX143689.0
Failure in > 2 csDMARDs90356.0
RF positive*121575.6
  1. *RF > 20 IU/mL was defined as positive
  2. CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score for 28 joints, RF rheumatoid factor, MMP-3 matrix metalloproteinase, MTX methotrexate, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs